Trial Profile
First clinical experiences with a new 99mTclabeled PSMA-inhibitor, [99mTc]mas-3-iodo-nal-k-sub-KuE (99mTc-PSMA I&S) for recurrent prostate cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2016
Price :
$35
*
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- 07 Jul 2016 New trial record